A new therapeutic indication of botulinum toxins: Sialorrhea

Acta Neurologica Taiwanica

Volumn 15, Issue 3, 2006, Pages 151-153

  Chen, Rou Shyan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; SNARE PROTEIN;

ABSENCE OF SIDE EFFECTS; ACETYLCHOLINE RELEASE; DENERVATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DYSPHAGIA; EDITORIAL; FACIAL NERVE INJURY; HEMATOMA; HUMAN; HYPERSALIVATION; INFECTION; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; PAIN; PAROTID GLAND; SALIVARY GLAND DUCT; SPASTICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

BOTULINUM TOXINS; HUMANS; SIALORRHEA;

EID: 33748769557     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (20)

1. Hsiung GY, Das SK, Ranawaya R, et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288-93.
2. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity and immunology. Muscle Nerve 1997;suppl 6:S146-68.
3. Wenzel RG. Pharmacology of botulinum neurotoxin serotype A. Am J Health-Syst Pharm 2004;61:S5-10.
4. Cordivari C, Misra VP, Catania S, et al. New therapeutic indications for botulinum toxins. Mov Disord 2004;19:S157-61.
5. Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J Neruol Sci 2005;235:1-9.
6. Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Move Disord 2004;19:S137-41.
7. Eleopra R, Tugnoli V, Quatrale R, et al. Different types of botulinum toxin in human. Mov Disord 2004;19:S53-9.
8. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004;19:S129-36.
9. Glickman S, Deaney CN. Treatment of relative sialorrhoea with botulinum toxin type A: description and rationale for an injection procedure with case report. Eur J Neurol 2001;8:567-71.
10. Townsend GL, Morimoto AM, Kralemann H. Management of sialorrhea in mentally retarded patients by transtympanic neurectomy. Mayo Clin Proc 1973;48:776-9.
11. Klem C, Mair EA. Four-duct ligation: a simple and effective treatment for chronic aspiration from sialorrhea. Arch Otolaryngol Head Neck Surg 1999;125:796-800.
12. Ethunandan M, Macpherson DW. Persistent drooling: treatment by bilateral submandibular duct transposition and simultaneous sublingual gland excision. Ann R Coll Surg Engl 1998;80:279-82.
13. Ellies M, Laskawi R, Rohrbach-Volland S, et al. Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 2003;61:454-7.
14. Suskind DL, Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 2002;112:73-81.
15. Dogu O, Apaydin D, Sevim S, et al. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93-6.
16. Jongerius PH, van den Hoogen FJ, van Limbeek J, et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 2004;114:620-7.
17. Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279-81.
18. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004;62:37-40.
19. Su CS, Lan MY, Liu JS, et al. Botulinum toxin type A treatment for Parkinsonian patients with moderate to severe sialorrhea. Acta Neurol Taiwan 2006;15:170-6.
20. Winterholler MG, Erbguth FJ, Wolf S, et al. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry 2001;70:417-8.